

**FOURTH INTERNATIONAL
SYMPOSIUM
ON CHIRAL DISCRIMINATION**

September 19 - 22, 1993, Montreal, Quebec, Canada

**QUATRIÈME
SYMPOSIUM INTERNATIONAL
DE CHIRALITÉ**

le 19 - 22 septembre, 1993, Montréal (Québec) Canada

March 25, 1993

Dr. Arthur Isenberg
Scientific Director
Council for Tobacco Research
900 3rd Ave. 4th Floor
New York, New York. 10022

Dear Dr. Isenberg:

We are pleased to announce that the 4th International Symposium on Chiral Discrimination (Quatrieme Symposium International de Chiralité) will be held in Montreal, Quebec, Canada on September 19-22, 1993. This symposium is the next in a series of international meetings which began in Paris, France in 1989 and have been held in Rome, Italy (1991) and Tubingen, Germany (1992); future meetings are scheduled for Stockholm, Sweden (1994) and St. Louis, U.S.A. (1995). The past meetings in this series have averaged 500 participants and we expect a similar number to attend the Montreal meeting, especially since this is the first International Symposium on Chiral Discrimination to be held on the North American Continent.

The International Symposia on Chiral Discrimination are multidisciplinary meetings designed to explore the effect of stereochemistry in the fields of chemistry, biology and pharmacology, as well as, the regulatory and industrial implications of this phenomenon. This is the principal international meeting for those working in the area of chirality and essential for people working on the development, testing and marketing of new drug substances.

The scientific program will consist of oral presentations by invited speakers and poster presentations. The topics which will be addressed during this meeting are listed in the enclosed brochure and include the following:

- Stereochemical issues in the agricultural and food industries
- International harmonization of stereoisomeric drug regulation
- Clinical implications of stereochemistry
- New approaches to practical stereoselective synthesis
- Chirality in ligand-biopolymer interactions
- Chirality as an investigative tool
- Stereochemical aspects of pharmacology and toxicology
- Non-chromatographic approaches to the determination of stereochemical purity and structure
- Chromatographic separation of stereoisomers

We are quite excited about this program which has attracted speakers from the forefront of their fields; for example, E.J. Corey will present the symposium's Key Note Address.


Chiral
Secretariat
Conference Office
McGill
University
550
Sherbrooke Street
West
West Tower
Suite 400
Montreal, Quebec
Canada
H3A 1B9
Telephone:
(514) 398 3770
Telefax:
(514) 398 4854
E-mail:
CHIRAL@550SHERB.LAN.MCGILL.CA

In view of your institution's interest in these areas, we would like to invite you to participate as a corporate sponsor in order to help ensure the success of this symposium.

In addition there will also be a limited number of exhibitor spaces available for rental. If you are interested, we can arrange for the committee member responsible for this aspect to contact you.

We hope that you will take this opportunity to share in this important event. If you would like more information, you can reach us through the conference office at the phone number indicated on the letter head or at our work places indicated below. We will be contacting you by phone in the next few weeks to discuss the possibility of your institution's participation.

Yours truly,



Irving Wainer, Ph.D. or
Chairman of the Organizing Committee

Professor and Director
Pharmacokinetics Division
Department of Oncology
McGill University
(514) 937-6011 (x3022)

Deborah Nicoll-Griffith, Ph.D.
Organizing Committee Member

Research Fellow
Dept. of Medicinal Chemistry
Merck Frosst Centre for
Therapeutic Research
(514) 428-8619

North American Organizing Committee

Darrell Abernathy, Brown University
Anne-Francoise Aubry, McGill University
William Duax, Medical Foundation of Buffalo
Joe Gall, University of Colorado
Romas Kaslauskas, McGill University
Sylvie Laganriere, Health Protection Board
James Longstreth, G.D. Searle and Co.
Scott Perrin, Regis Chemical Co.,
Apryll Stalcup, University of Hawaii

Irving Wainer, McGill University

Daniel Armstrong, University of Missouri
Mitchell Cayen, Schering-Plough Research
Jamali Fakhreddin, University of Alberta
Steven Hanessian, University of Montreal
Karin Kirkland, ICI Pharmaceuticals Group
David Lloyd, McGill University
Deborah Nicoll-Griffith, Merck Frosst
William Pirkle, University of Illinois
David Trigg, University of Buffalo